Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines
2024年8月14日 - 2:00PM
Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage
biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that the
United States Patent and Trademark Office (USPTO) has issued U.S.
Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope
Vaccine”.
The newly issued patent describes Nykode’s fully
individualized neoantigen based vaccine, VB10.NEO, which is in
development for the treatment of locally advanced or metastatic
solid tumours. The 20 year expiration date of this patent is
January 5, 2037. Related patents were previously granted to the
company in Russia, India, and Australia.
Michael Engsig, CEO of Nykode, said, “We
are very pleased with the granting of this important patent in the
U.S., a key market for Nykode. Continuously expanding our patent
protection is a core strategy for us. The granting of this patent
is a testament to the world-class innovation taking place in
Nykode's labs. We remain dedicated to pushing the boundaries of
what's possible in medicine, bringing hope to patients and their
families around the globe.”
About VB10.NEOVB10.NEO is a
proprietary individualized neoantigen vaccine in development for
the treatment of locally advanced or metastatic solid tumors under
an exclusive, worldwide clinical collaboration with Genentech, a
member of the Roche Group. The vaccine is designed to be produced
on-demand according to the neoantigen profile of an individual
patient. Neoantigens are proteins generated by tumor-specific
mutations not present in normal tissues and are thus an attractive
target for cancer immunotherapy as they may be recognized as
foreign by the immune system.
Nykode is currently conducting a clinical study
evaluating VB10.NEO: VB N-02, an open-label Phase 1b,
dose-escalation study of the safety and antigen-specific immune
responses elicited by VB10.NEO in combination with Roche’s
checkpoint inhibitor atezolizumab in patients with locally advanced
and metastatic tumors (NCT05018273).
About Nykode TherapeuticsNykode
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to the discovery and development of novel immunotherapies
with a focus on the treatment of cancer and autoimmune diseases.
Nykode’s modular vaccine technology specifically targets antigens
to antigen presenting cells (APC), which have been shown to induce
a broad, strong and long-lasting antigen specific immune response
in cancer, which correlates with clinical responses.
Nykode’s lead product candidates are VB10.16, a
therapeutic vaccine for the treatment of HPV16 induced malignancies
which demonstrated favorable safety and efficacy results from its
Phase 2 trial for the treatment of cervical cancer. VB10.16 is
being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer. VB10.NEO, an individualized cancer
neoantigen vaccine, is exclusively out-licensed to Genentech, a
member of the Roche Group.
The Company’s partnerships include Genentech
within oncology and a multi-target collaboration with Regeneron in
oncology and infectious diseases.
Nykode is also utilizing its APC-targeted
technology to create an inverse vaccine platform for the potential
use in autoimmune disorders, organ transplant rejections, anti-drug
antibody reactions and allergy.
Nykode Therapeutics’ shares are traded on the
Oslo Stock Exchange (OSE: NYKD). Further information about Nykode
Therapeutics can be found at http://www.nykode.com.
Forward-looking statements for Nykode
Therapeutics
This announcement and any materials distributed
in connection with this announcement may contain certain
forward-looking statements. By their nature, forward-looking
statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events
and circumstances that may not prove accurate. A number of material
factors could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking
statements.
Contact for Nykode Therapeutics
ASA:
Head of Investor Relations, Alexandra DeschnerNykode
Therapeutics ASA IR@nykode.com
Nykode Therapeutics ASA
Oslo Science ParkGaustadalléen 21N-0349 Oslo, Norway